Benitec Biopharma
BNTC
3 hedge funds and large institutions have $743K invested in Benitec Biopharma in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more funds holding
Funds holding: 1 → 3 (+2)
69% less capital invested
Capital invested by funds: $2.38M → $743K (-$1.63M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Evanson Asset Management
Carmel,
California
|
+$63.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$505K |
BNTC Hedge Fund Activity: Q1 2016 in Review
3 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2016, worth a combined $743K — down 69% from $2.38M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BNTC positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Evanson Asset Management, opening a new position worth an estimated $63.2K. The largest seller was Sabby Management, cutting an estimated $505K.
- 3 institutional investors held Benitec Biopharma (BNTC) as of Q1 2016, up from 1 in Q4 2015.
- Funds reported $743K of Benitec Biopharma stock for Q1 2016, down 69% quarter-over-quarter.
- 2 funds opened new Benitec Biopharma positions in Q1 2016 and 0 closed out, a net change of +2 holders.
- The largest Benitec Biopharma buyer in Q1 2016 was Evanson Asset Management, an estimated $63.2K added.
- The largest Benitec Biopharma seller in Q1 2016 was Sabby Management, an estimated $505K sold.
Based on aggregated 13F filings for Q1 2016.